NewAmsterdam Pharma (NAMS) Total Current Liabilities (2021 - 2026)

NewAmsterdam Pharma has disclosed Total Current Liabilities across 6 years of filings, most recently posting $67.4 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $67.4 million, up 64.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $67.4 million (up 64.79% YoY), and the FY2025 annual result was $85.8 million, down 19.76% from the prior year.
• Total Current Liabilities came in at $67.4 million for Q1 2026 at NewAmsterdam Pharma, down from $85.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $106.9 million in Q4 2024 to a low of $41743.9 in Q2 2023.
• The 5-year median for Total Current Liabilities is $47.6 million (2023), against an average of $52.4 million.
• Across the five-year window, Total Current Liabilities soared 108435.58% in 2024 and slumped 31.5% in 2025, its largest moves.
• NewAmsterdam Pharma's Total Current Liabilities stood at $36.2 million in 2022, then surged by 37.92% to $49.9 million in 2023, then surged by 114.28% to $106.9 million in 2024, then decreased by 19.76% to $85.8 million in 2025, then dropped by 21.41% to $67.4 million in 2026.
• The last three Total Current Liabilities figures came in at $67.4 million (Q1 2026), $85.8 million (Q4 2025), and $58.3 million (Q3 2025), per Business Quant data.